Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 1

Conditions

Multiple Myeloma 4Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lymphoma, Non-Hodgkin 2Pancreatic Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 166Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 84Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × dinaciclib × Clear all
NCT01676753 2022-09-21

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

University of California, San Francisco

Phase 1 Completed
32 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01624441 2018-03-30

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00732810 2015-08-05

SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)

Merck Sharp & Dohme LLC

Phase 2 Completed
97 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡